1. Introduction
===============

Tight junctions (TJs) are the apical junctional complex in epithelial and endothelial cells ([@b1-or-36-01-0003]). TJs play a key role in maintaining distinct tissue spaces and regulating paracellular flux of small molecules and inflammatory cells, as well as promoting bi-directional signaling between the intracellular and extracellular compartments ([@b2-or-36-01-0003]--[@b4-or-36-01-0003]). Furthermore, tumor differentiation is related to the reduction of TJs, and tumor cells must overcome the frontline structures of TJs in order to successfully metastasize ([@b5-or-36-01-0003]--[@b7-or-36-01-0003]).

The JAM family belongs to the immunoglobulin subfamily involved in the formation of TJ in most cell types, including leukocytes, platelets, endothelial and epithelial cells ([@b2-or-36-01-0003],[@b8-or-36-01-0003]--[@b10-or-36-01-0003]). JAMs have been reported to regulate epithelial TJ assembly, and interact in both a homo- and heterotypic fashion, as well as with integrins ([@b3-or-36-01-0003],[@b11-or-36-01-0003],[@b12-or-36-01-0003]). The JAM family comprises five members, namely JAM-A, JAM-B, JAM-C, JAM-4, and JAM-like ([@b13-or-36-01-0003]--[@b16-or-36-01-0003]). There are many differences between JAM-B and the other JAM family members. This review will highlight that which is currently known about the structure, function, and mechanisms of action of JAM-B and potential areas for future study.

2. Structure of the JAM family
==============================

Members of the JAM family are type I transmembrane glycoproteins consisting of a short N-terminal signal peptide, two immunoglobulin-like domains, one transmembrane domain and one cytoplasmic tail of variable length containing a C-terminal PDZ-domain domain ([@b4-or-36-01-0003],[@b17-or-36-01-0003]--[@b20-or-36-01-0003]). In the case of JAM-A, the sequence was described by multiple investigators as two C2-type domains in mouse ([@b10-or-36-01-0003]) and two V-type domains in human ([@b2-or-36-01-0003]). However, the Ig-like domains of JAM-B and JAM-C are composed of V type and C2 type ([@b18-or-36-01-0003]) ([Fig. 1](#f1-or-36-01-0003){ref-type="fig"}). A J-like sequence is contained in the V domain and an extra disulfide bridge between cysteines involved incorporated in the C2-type domain ([@b19-or-36-01-0003]).

Some studies have found that JAM-A has a three amino acid sequence (Val-Leu-Val) in the connection between the two Ig-like domains which causes the distal Ig-like domains to bend and bind to another three amino acid sequence (Arg-Leu-Glu) in the V type Ig-like domains and dimerise ([@b20-or-36-01-0003],[@b21-or-36-01-0003]). A JAM-A dimer at the surface of cells may interact in a *trans* orientation with another dimer of JAM2 expressed by the adjacent cell, forming a tetramer. The successive JAM tetramer would be able to structure a zipper-like structure surrounding the cell at the apical cells border. It was found that JAM-B (Arg-Leu-Glu) and JAM-C (Arg-Ile-Glu) could form the same type of dimerisation motifs as seen in JAM-A ([@b19-or-36-01-0003]).

3. Expression profiles and subcellular localization
===================================================

The JAM family exhibits different expression profiles and transcript level in various tissues, organs and tumors ([Table I](#tI-or-36-01-0003){ref-type="table"}). Overall, as an important member of the TJ complex, JAMs are generally expressed in subsets of leukocytes, as well as in epithelial and endothelial cells ([@b22-or-36-01-0003],[@b23-or-36-01-0003]). However, compared with JAM-A and JAM-C, JAM-B displays a restricted distribution. It is expressed in the junctions of endothelial cells of different vessels, but mostly localizes in high endothelial venules ([@b13-or-36-01-0003],[@b25-or-36-01-0003]).

Amongst different types of tumors, it is difficult to quantitatively analyze differences in the expression of the JAM family. Therefore, the differential expression of JAM-B in cancer and normal tissues must be compared in a similar tumor type. Multiple studies have shown that the expression of JAM-B shows significant differences when comparing normal and cancerous tissues with the data presented in [Table II](#tII-or-36-01-0003){ref-type="table"}.

4. Related signaling pathways
=============================

JAM receptor
------------

As reported, classical JAMs, containing an intracellular PDZ binding domain which may act as an anchor for scaffolding adaptor proteins, can mediate cellular functions, embryonic development ([@b26-or-36-01-0003]), junction assembly, spermatogenesis, paracellular permeability, leukocytic transmigration, angiogenesis, tumor metastasis and cell proliferation through binding and interacting with receptors such as ligand and integrin ([@b17-or-36-01-0003],[@b27-or-36-01-0003]--[@b33-or-36-01-0003]). The heterodimeric transmembrane receptors, the integrins, contain α- and β-subunits, which mediate cell-to-cell adhesive interactions.

Role of the receptor in JAM-B functions
---------------------------------------

There are several studies which report JAM-B interacting with JAM-C and the integrin α4β1, forming multimer interactions with integrin counter-receptors. JAM-B can interact with the integrin α4β1, but this is dependent on the presence of JAM-C. In 1996, Butcher and Picker described integrin-mediated T-lymphocyte adhesion inflamed endothelium through VCAM-1 ([@b34-or-36-01-0003]). However, whether the integrin could engage JAM-B and VCAM-1 simultaneously through different binding sites is still unclear. However, JAM-B and VCAM-1 may interact with one another laterally and reinforce integrin through conformational changes ([@b35-or-36-01-0003]). Other reports claim that on human circulating platelets, dendritic cells, NK cells, and subsets of T and B cells, JAM-C plays an extended role as the leukocyte counter receptor for JAM-B expressed on endothelial cells ([@b11-or-36-01-0003],[@b36-or-36-01-0003]--[@b40-or-36-01-0003]). In 2009, Ludwig *et al* found that using a model of DNFB-induced contact hypersensitivity, JAM-B played a role in rolling and firm adhesion of T lymphocytes by interacting with α4β1 ([@b41-or-36-01-0003]). However, a recent study proposed JAM-B to play an independent role in leukocyte transmigration.

Functional epitopes in JAM-B proteins
-------------------------------------

JAM-B has been reported involved in many kinds of biological processes, for instance, leukocyte migration ([@b39-or-36-01-0003],[@b42-or-36-01-0003]--[@b44-or-36-01-0003]), spermatogenesis ([@b45-or-36-01-0003]) and angiogenesis ([@b46-or-36-01-0003]) through its interaction with JAM-C. Previous study has shown that blocking the interactions of JAM-B and -C can reduce monocyte numbers in the ablumenal compartment by increasing reverse transmigration rather than through reducing transmigration ([@b47-or-36-01-0003]).

The effect of JAM-B and JAM-C in leukocyte accumulation during inflammation has also been monitored ([@b39-or-36-01-0003],[@b43-or-36-01-0003],[@b48-or-36-01-0003]). For example, a study suggested anti-JAM-B and anti-JAM-C antibodies played a role of addition agent in blocking leukocytes infiltration in the model of allergic contact dermatitis, indicating that the actions of JAM-B and -C are indispensable for development of cutaneous inflammation ([@b50-or-36-01-0003]). Previous study has shown that blocking the interactions of JAM-B and -C can reduce monocyte numbers in the ablumenal compartment by increasing reverse transmigration rather than through reducing transmigration. Overall, the results indictate that the blocking of JAM-B/-C interactions decreased the number of monocytes in inflamed tissues owing to considerably increased level of reverse-transmigrated monocytes in the peripheral blood.

Signaling pathways
------------------

The cellular localization of JAMs is related to specific signals of the extracellular environment. Phosphorylation of the cytoplasmic tail of JAMs plays a key role in the mechanism of regulating the localization of JAMs. The classical JAM proteins all contain C-terminal PDZ-binding domains which can be modified by kinases and may facilitate the interaction with PDZ-containing proteins, such as TJ-associated cytoplasmic proteins AF6, PAR3, ZO1, CASK, MAGI and MUPP1 ([@b15-or-36-01-0003],[@b50-or-36-01-0003]--[@b54-or-36-01-0003]). In 2003, Ebnet *et al* showed that JAM-B and JAM-C could directly associate with PAR-3 through its first PDZ domain, and could also associate with protein ZO-1 in a PDZ domain-dependent manner ([@b55-or-36-01-0003]). Recently, antibodies against murine JAM-B inhibited microvessel endothelial cell proliferation were demonstrated through *in vitro* endothelial network formation assays and *ex vivo* aortic rings. This research also showed that JAM-B can negatively regulate pro-angiogenic pathways and inhibit VEGF-induced ERK1/2 activation through integrin activation in MAPK pathway ([@b56-or-36-01-0003]).

5. Multiple roles of JAM-B in cancer
====================================

Following the investigation of JAM-B protein involvement in the control of cellular motility and formation of cellular projections in cancer cells, a number of researchers have focused on the roles of JAM-B and regulation of this molecule in cancer cells and tissues. Clinical studies have mentioned different expression profiles and roles of JAM-B in various types of cancers. The inconsistency of the results in different cancers has led to an uncertainty regarding the role of JAM-B in carcinogenesis.

Tumor metastasis is the movement or spreading of tumor cells from the primary site to a distant one. Circulating tumor cells, separated from primary tumor, can interact with vascular endothelial cells during hematogenous metastatic dissemination. Metastatic and invasive potential of a tumor cell depends on the expression of various proteins at each step of the metastatic cascade. Numerous studies showed JAM-B played an important role in the metastasis of tumor cells ([@b57-or-36-01-0003]--[@b59-or-36-01-0003]).

JAM-B in gastric carcinoma
--------------------------

Gastric cancer, one of the most common malignancies, is the second leading cause of cancer-related death globally. Many patients who had gastric cancer previously could still suffer from tumor recurrence and metastasis following curative gastrectomy. Deregulation of the expression and function of TJ proteins leads to the initiation and progression of cancer by activation of cytoskeleton mechanism. Hajjari *et al* examined the changes in expression levels of genes encoding tight junction-associated proteins of JAM-B and JAM-C in gastric adenocarcinoma in comparison with their corresponding marginal normal gastric tissues from the same patients. They found that JAM-B was upregulated significantly in tumor samples compared with adjacent normal tissues and was higher in high grade tumors than in the low grade and intermediate grade tumors. Moreover, they showed JAM-B and JAM-C activated the expression of actin filament-associated protein (AFAP) gene as a downstream factor of JAM-B and JAM-C and this resulted in a significantly higher expression of AFAP ([@b57-or-36-01-0003]). Recently, whole genome and transcriptome sequencing in primary and peritoneal metastatic gastric carcinoma indicated JAM-B was only expressed in primary tumors ([@b58-or-36-01-0003]). Overall, deregulation of JAM-B and JAM-C expression may potentially be involved in progression of gastric adenocarcinoma tumors. However, JAM-A was downregulated in gastric cancer tissues compared to adjacent non-tumor tissues from the same patients, and low JAM-A expression contributed to poor clinical outcome and increased cell invasion and migration in gastric cancer ([@b59-or-36-01-0003]).

JAM-B in colorectal cancer
--------------------------

Recently, Kok-Sin *et al* studied 150 colorectal tissues with the methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA), and they found JAM-B was expressed at very low levels in colorectal cancer due to JAM-B genes being hypermethylated on promoters in CpG islands ([@b60-or-36-01-0003]). The hypermethylation of the promoter and the downregulation of JAM-B in colon cancer were also supported by a report from 2011 ([@b61-or-36-01-0003]). Another recent study showed the expression changes of cell-cell adhesion-related genes among 26 colorectal cancer, 42 adenoma and 24 normal mucosa samples. Between these tissue types, different expression were observed in the mRNA levels of JAM-B genes encoding adherence junction proteins and JAM-B was expressed at lower levels in adenocarcinoma and adenoma than in normal colonic mucosa. Further, JAM-B has the lowest expression levels in adenoma ([@b62-or-36-01-0003]).

JAM-B in glioma
---------------

Brain invasion is a biological hallmark of glioma which contributes to its aggressiveness and prognosis. Deregulated expression of JAMs in glioma cells has been implicated in this process. Recently, a study showed that JAM-B was aberrantly expressed in glioma as a high affinity JAM-C ligand. The interaction of JAM-B and JAM-C could activate c-Src proto-oncogene, which is known as a central upstream molecule in the pathways regulating cell invasion and migration. Also it was shown that JAM-B/C blocking antibodies impaired *in vivo* glioma invasion and proliferation in mice ([@b63-or-36-01-0003]). Magnetic nanoparticle mediated JAM-2 silencing also inhibited the growth and migration of glioma *in vitro* and *in vivo* ([@b64-or-36-01-0003]). A similar study from the same laboratory also found that the silencing of JAM-2 by proton-sponge coated quantum dots inhibited the migration of glioma *in vitro* through NOTCH pathway blockage ([@b65-or-36-01-0003]). In short, targeting of the JAMs family may provide a potential lead for the treatment of human gliomas.

JAM-B in melanoma
-----------------

Melanoma is the most dangerous type of skin cancer. Many factors have been proposed to influence the metastasis of melanoma in patients. Arcangeli *et al* indicted JAM-B expressed by endothelial cells was involved in melanoma cell metastasis via its interaction with JAM-C on tumor cells. Furthermore, using a JAM-B-deficient mouse model, it was found that the differential migration disappeared between JAM-C expressing cells and JAM-C silenced cells, revealing that JAM-B acted as a counter-receptor for JAM-C mediated reservation of melanoma cells in the lungs ([@b66-or-36-01-0003]).

JAM-B in esophageal squamous cell carcinoma (ESCC)
--------------------------------------------------

Esophageal squamous cell carcinoma is an aggressive and malignant tumor for which there is limited treatment option. The reason for this is that most cases are diagnosed late, and patients are already in the advanced stages of the disease. Lymph node metastasis often arises from this type of cancer, due to the rich lymphatic drainage system in the esophagus. Recently, it was demonstrated that the methylation of JAM-B was increased in the region downstream of the gene and its expression was decreased ([@b67-or-36-01-0003]). Furthermore, a similar result showed that the expression JAM-B was downregulated and JAM-B was identified as a key player in the signal transduction networks in ESCC ([@b68-or-36-01-0003]).

JAM-B in breast cancer
----------------------

In females, breast cancer is the leading cancer with high incidence and frequently diagnosed malignancy, with lower survival rates in patients. JAM-B is a necessary component of apical junctional components. Recently, Coradini *et al* reported that mutant p53 tumors of breast cancer were characterized by a dramatic under-expression of several genes coding for apical junctional components ([@b69-or-36-01-0003]). Further, a report from Bhan *et al* stated that JAM-B was associated with breast cancer progression ([@b70-or-36-01-0003]). In 2010, our laboratory showed JAM-B had a significantly lower level in breast tumors from patients who developed metastasis than those who were disease-free. We concluded that JAM-B decreased migration and metastasis of breast cancer cells. In contrast, JAM-A expression was upregulated in breast cancer tissues compared to the normal specimen and was correlated to reduced survival of breast tumor patients, thus JAM-A overexpression could be a possible mechanism promoting breast cancer cell migration ([@b71-or-36-01-0003]).

JAM-B in lung cancer
--------------------

Lung cancer is a malignant lung tumor characterized by uncontrolled cell proliferation in tissues of the lung. JAM-2 was negatively expressed in normal mouse lung, but positively expressed in spleen and lymph nodes surrounding the lung ([@b72-or-36-01-0003]). An interesting discovery showed that overexpression of JAM-B in a trisomy-21 mouse model of Down\'s syndrome was responsible for inhibiting VEGF-induced angiogenesis and, thus, restraining tumor effects in a lung carcinoma mouse model ([@b73-or-36-01-0003]). Conversely, the expression level of JAM-A in lung tumor tissues was higher than corresponding normal lung tissues and served as a negative predictor of survival in lung cancer patients. Thus, JAM-A contributes to lung cell growth through cell cycle regulation ([@b74-or-36-01-0003]).

JAM-B in oral squamous cell carcinoma
-------------------------------------

Oral squamous cell carcinoma (OSCC) characteristically metastasizes from the primary organ to regional lymph nodes in the early stages of the cancer. It was demonstrated that JAM-B correlated with the metastatic potential, as it was upregulated in human oral cancer LNM Tca8113 cells which metastasized to lymph nodes at an higher rate than its parental cell line Tca8113 ([@b75-or-36-01-0003]). Therefore it was suggested JAM-B acts as a potential factor for the metastasis of OSCC.

Role of JAM-B in other diseases
-------------------------------

Zhang *et al* examined the relationship between JAM-B polymorphisms and the risk of rheumatoid arthritis (RA) among the Chinese population and excluded the affiliation between JAM-B polymorphisms and a decreased risk of RA ([@b76-or-36-01-0003]). A study on inflammation indicated JAM-B expression was restricted to the endothelium of arterioles in and adjacent to lymphocytic inflammation sites but was not discovered in liver specimens, signifying JAM-B may only be inducible in some inflammatory tissue types ([@b11-or-36-01-0003]). Another similar study showed that JAM-B was involved in leukocyte extravasation to inflammation sites ([@b49-or-36-01-0003]). Tumor angiogenesis is a fundamental step of cancer progression. Moreover, Meguenani *et al* reported that JAM-B interfered with angiogenic VEGF/VEGFR2 signaling which is a major pathway necessary for tumor angiogenesis, suggesting JAM-B could provide a useful possibility for the diagnosis and treatment of relevant diseases ([@b56-or-36-01-0003]).

6. Conclusion
=============

Recent studies focusing on the interaction of JAMs have determined multiple homophilic and heterophilic *cis*/*trans*-interactions. Further, regulation of JAM functions arises by establishing intracellular/extracellular multiprotein complexes. The family of JAMs shows stability in expression levels under various conditions, indicating a vital role under pathological and homeostatic conditions ([@b42-or-36-01-0003],[@b77-or-36-01-0003]). JAMs also play an important role in decreasing epithelial paracellular permeability. An increasing number of studies has concentrated on the role of JAMs in tumors. It is clear that JAMs regulate cell growth, invasion and migration. Perturbed expression of JAMs has been observed in various malignancy types. The abnormal expression of certain JAMs is related to disease progression and poor prognosis. Different JAMs may play contrasting roles in the same cancer, while the same JAM may undertake converse roles in different tumor types.

7. Future perspectives
======================

JAM-B interact with various receptors and cytokines to modulate downstream signal transduction. Most studies concerning JAM-B showed it does not assume a single role in regulating tumors, but always with JAM-C-dependence. JAM-B/-C is an important complex in cell-cell signaling. Its molecular mechanism of action is in need of further investigation. Many researchers have shown that JAM-B is an important regulator in various diseases. According to the above cited studies, the expression level of JAM-B is different in various tumors compared with normal tissues from the same patients. Thus, JAM-B may have different potentiality in the regulation of cancer metastasis. Further, insight into the detailed mechanisms involved in JAM-B-mediated regulation would be useful in the understanding its function and role in tumorigenesis and tumor metastasis. Further investigations will highlight its clinical significance and application for predicting prognosis. In the future JAM-B may well provide preoperative diagnosis and a new avenue for targeted therapy in certain malignancies.
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###### 

Classic JAM family: Tissue distribution and main functions.

          Cell expression                                                                                                                                   Tissue expression                                                                                                                                References
  ------- ------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------
  JAM-A   Epithelial cells, endothelial cells, leukocytes, platelets, spermatozoa/Sertoli cells, HSC                                                        Brain, heart, blood, bone marrow, intestine, kidney, liver, lung, pancreas, spleen, lymph node, skin, placenta, testis                           ([@b2-or-36-01-0003],[@b24-or-36-01-0003],81--87)
  JAM-B   HEV, lymphatics, Sertoli cells, HSC, NSC vascular and lymphatic endothelial cells                                                                 Heart, placenta, testis, kidney, lymph nodes, intestine, brain, lymph node (HEV), skin, heart, lung                                              ([@b18-or-36-01-0003],[@b36-or-36-01-0003],[@b38-or-36-01-0003],[@b46-or-36-01-0003],78,88,89)
  JAM-C   Vascular and lymphatic endothelial cells, DC, Pl, NK, HEV, lymphatics, platelets, spermatid, HSC, Schwann cells, fibroblast, leukocytes (human)   Brain, bone marrow, heart, smooth muscle, uterus, lung, liver, kidney, spleen, testis, nerve, lymph node (HEV), skin, cornea, placenta, testis   ([@b18-or-36-01-0003],[@b36-or-36-01-0003],86,88,89)

###### 

Regulation of CCNs in cancer.

  Tumor type          JAM-B expression level
  ------------------- ------------------------
  Gastric carcinoma   **↑**
  Colorectal cancer   ***↓***
  Glioma              **↑**
  ESCC                ***↓***
  Breast Cancer       **↑**/***↓***
  NSCLC               ***↓***
  OSCC                **↑**
  RA                  ***↓***

ESCC, esophageal squamous cell carcinoma; NSCLC, non-small cell lung cancer; OSCC, oral squamous cell carcinoma; RA, rheumatoid arthritis. ↓: JAM-B is lower expressed in tumor tissue than in corresponding normal tissue; ↑: JAM-B is higher expressed in tumor tissue than in corresponding normal tissue; ↑/↓: JAM-B expression in tumor is controversial.
